Featured ArticlesRosaceaThe Latest

Review Highlights Need for More Effective Rosacea Treatments

By February 1, 2021May 25th, 2021No Comments

Featured Article

Featured Article

“The inflammatory pathways underlying rosacea are becoming increasingly elucidated. What remains unknown is the mechanism of progression of these pathways, and how they can result in papules/pustules and/or phyma in some patients but not others”

More Rosacea Articles

“The inflammatory pathways underlying rosacea are becoming increasingly elucidated. What remains unknown is the mechanism of progression of these pathways, and how they can result in papules/pustules and/or phyma in some patients but not others.”

Heather Onorati

While much progress has been made in better understanding the pathogenesis of rosacea, a need remains for more effective treatments to address the underlying inflammation and to improve clearance.

Current therapies for facial erythema provide temporary relief and are not consistent at helping patients achieve complete clearance of papules and pustules, according to authors Jerry Tan, MD, of Western University in Ontario, Canada, and J. Mark Jackson, MD, of the University of Louisville in Louisville, Ky, who published a review in the Journal of Drugs in Dermatology (“Treating Inflammation in Rosacea: Current Options and Unmet Needs”). They examined what is known about the underlying inflammatory nature of rosacea and its available treatments.

Ideally, the future of rosacea treatment should include addressing both the papules and pustules  as well as the inflammatory pathways leading to erythema and phyma, the authors say. Longer-term control and the ability to reduce the signs and symptoms of rosacea would be an important advance, they write.

Heather Onorati is an experienced medical writer and editor with more than 20 years covering the dermatology industry

Discover new clinical findings in Rosacea.  View the latest articles, case reports, supplements, Editorials,  and more.

 

You May Also Like

Journal of Drugs in Dermatology JDD Article about The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients

The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients

| Featured Articles, Latest News, Skin Cancer | No Comments
From the Vault: Fecal transplant may revive immunotherapy responses in melanoma We pulled this February 2024 vault article because it’s been a popular read. It’s a focused review of microbiota‑modulating…
Journal of Drugs in Dermatology JDD Article about GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities

GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities

| Featured Articles, Hidradenitis Suppurativa, Latest News | No Comments
Metabolic drugs for HS? GLP‑1 receptor agonists show promise beyond weight loss If you haven’t yet, dig into this recent JDD article about GLP-1 receptor agnosists and hidradenitis suppurativa. Hidradenitis…

Isotretinoin Does Not Increase the Risk of Inflammatory Bowel Disease: A TriNetX Retrospective Cohort Analysis

| Acne, Featured Articles, Latest News, Medical Derm | No Comments
Isotretinoin and IBD — large real‑world data offer reassurance In one of our recent JDD articles, a retrospective cohort using the TriNetX network compared acne patients exposed to long‑term, low‑dose…

Leave a Reply